Inge Marie Svane
24
3
3
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.8%
5 terminated/withdrawn out of 24 trials
73.7%
-12.8% vs industry average
0%
0 trials in Phase 3/4
64%
9 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Role: lead
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Role: lead
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Role: lead
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
Role: lead
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Role: lead
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Role: lead
TIL Therapy for Metastatic Renal Cell Carcinoma
Role: lead
Adoptive Cell Therapy Across Cancer Diagnoses
Role: lead
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Role: lead
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
Role: lead
Melanoma Metastasized to the Brain and Steroids
Role: lead
Dual Vaccine Trial in Myeloproliferative Neoplasms
Role: lead
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Role: lead
Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis
Role: lead
Vemurafenib and TIL Therapy for Metastatic Melanoma
Role: lead
Peginterferon and TIL Therapy for Metastatic Melanoma
Role: lead
Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients
Role: lead
TIL Therapy for Metastatic Ovarian Cancer
Role: lead
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
Role: lead
IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.
Role: lead